Showing 211-220 of 1893 results for "".
ICD-10: Facts, Myths, and Solutions
https://practicaldermatology.com/topics/practice-management/facts-mythsand-solutions/21422/With the deadline for implementation of the new Medicare coding system just months away, physicians need to prepare their practices for a significant transition.Laser Tattoo Removal and the Use of Stacked Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-tattoo-removal-and-the-use-of-stacked-treatments/19309/Tattoo removal procedures have been offered since the late 1990's, but are more effective than ever. This improvement is due to the implementation of stack treatments, during which four sessions can be performed at one time. To show the advances in this procedure, Dr. Joel Schlessinger walks you thrPart 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benNoah Worcester 2024: Dr. Cohen on Lasers
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-cohen-lasers/24578/Joel L. Cohen, MD, FAAD, summarizes his lecture on laser resurfacing and perioral rejuvenation at the 2024 Noah Worcester Dermatological Society meeting.Choosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.Landing in Dermatology
https://practicaldermatology.com/series/scientifically-speaking/landing-in-dermatology/20129/Humberto Antunes talks to host Joel L. Cohen, MD about how he got his start in dermatology and why the field appealed to him.Understanding and Addressing the Impact of Plaque Psoriasis Among Patients with Skin of Color
https://practicaldermatology.com/topics/psoriasis/understanding-and-addressing-the-impact-of-plaque-psoriasis-among-patients-with-skin-of-color/23763/Patients, physicians, and others are joining together to elevate the level of care for patients with skin of color who develop psoriatic disease.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Cutera, Galderma Acne Treatments; Alma's TED; Diversity Initiatives
https://practicaldermatology.com/topics/practice-management/dermwiretv-cutera-galderma-acne-treatments-almas-ted-diversity-initiatives/20084/There are two new options for treating acne. Cutera introduces the AviClear acne device; Galderma launches Twyneo Cream. Joshua Zeichner, MD weighs in. Lady Dy, MD discusses Alma’s TED device, a non-invasive, non-traumatic option to address hair loss. New initiatives announced at or in conjunction wEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments i